Product
Covishield
2 clinical trials
2 indications
Indication
COVID-19Indication
COVID-19 vaccineClinical trial
Phase IIb, Randomized, Double-blind, Non-inferior, Multicenter Study to Evaluate the Safety and Immunogenicity of the Self-replicating Nanoparticle Carrier Replicon RNA Carrier (repRNA) Vaccine in Adults 18 to 65 Years of AgeStatus: Not yet recruiting, Estimated PCD: 2023-03-01
Clinical trial
Phase 3, Randomized, Multi-Centric, Open-labeled Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose in Participants Previously Vaccinated With EUA VaccinesStatus: Completed, Estimated PCD: 2022-05-03